Cognizant Partners with NVIDIA to Apply Generative AI in Drug Discovery

Cognizant announces a strategic collaboration with NVIDIA to leverage generative AI (gen AI) technology through the NVIDIA BioNeMo platform. This partnership aims to revolutionize drug discovery processes within the life sciences industry, offering solutions to complex challenges and accelerating the development of life-saving treatments.

Addressing Challenges in Drug Discovery:

Traditional drug discovery methodologies are known for their complexity and resource-intensive nature. Cognizant aims to tackle these challenges by harnessing the power of generative AI, which enables researchers to sift through extensive datasets more rapidly and accurately predict interactions between drug compounds.

Quote from Anna Elango, EVP of Cognizant's Core Technologies & Insights:

"More than any other technological breakthrough in recent decades, generative AI has the potential to revolutionize the way new drugs are researched, developed and brought to market, making the creation of lifesaving discoveries faster, smarter and more accessible to all."